Vitry sur Seine, France

Florence Cabon-Georget

This inventor holds 2 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignee: Centre National De La Recherche Scientifique. Active years: 2008-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Florence Cabon-Georget. Retrieved from https://idiyas.com/inventor/florence-cabon-georget

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 50.0


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 52(Granted Patents)


Company Filing History:


Years Active: 2008-2012

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Florence Cabon-Georget: Innovator in Cancer Treatment

Introduction

Florence Cabon-Georget is a notable inventor based in Vitry sur Seine, France. She has made significant contributions to the field of cancer treatment through her innovative research and patented inventions. With a total of 2 patents, her work focuses on developing targeted therapies that aim to combat cancer at the molecular level.

Latest Patents

One of her latest patents is centered around a SiRNA-based cancer treatment. This invention involves a double-strand oligonucleotide that includes two complementary oligonucleotide sequences forming a hybrid. Each sequence contains one to five unpaired nucleotides at either the 3' or 5' ends, extending beyond the hybrid. This oligonucleotide sequence is designed to be substantially complementary to a target sequence belonging to a DNA or RNA molecule that is specifically repressed, particularly targeting genes coding for angiogenic factors.

Another significant patent by Cabon-Georget describes inhibitor oligonucleotides and their use for the specific repression of harmful genes. The method outlined in this patent involves administering a therapeutically effective amount of a pharmaceutical composition containing at least one double-stranded oligonucleotide. This oligonucleotide includes two complementary sequences forming a hybrid, with one sequence being substantially complementary to a target sequence belonging to a DNA or messenger RNA molecule of a gene coding for a mutated or nonmutated androgen receptor.

Career Highlights

Florence Cabon-Georget is affiliated with the Centre National de la Recherche Scientifique, a prestigious research institution in France. Her work has been instrumental in advancing the understanding of gene therapy and its applications in treating cancer.

Collaborations

Throughout her career, Cabon-Georget has collaborated with esteemed colleagues, including Annick Harel-Bellan and Slimane Ait-Si-Ali. These collaborations have further enriched her research and contributed to the development of innovative cancer treatments.

Conclusion

Florence Cabon-Georget's contributions to cancer treatment through her patented inventions highlight her role as a leading innovator in the field. Her work continues to pave the way for new therapeutic strategies that may significantly impact cancer care in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…